Reinach, Switzerland, 26 November 2009. The Extraordinary General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors. A total of 74 shareholders were present at the meeting that took place in Reinach today. 2,981,585 shares were represented, or 14.1% of the total number of shares issued (21,094,104).
ARPIDA SHAREHOLDERS’ MEETING TO TAKE PLACE ON 26 NOVEMBER 2009
Reinach, Switzerland, 4 November 2009. Arpida Ltd. (SIX: ARPN) today announced that it has entered into a definitive agreement to combine its business with that of Evolva SA. The combination agreement sets out the details of the proposed transaction and has been approved by the Boards of Directors of both companies and by investors, holding a majority of Evolva AG’s shares. In addition, independent valuation experts assessed Evolva SA’s business activities and concluded that the value, attributed to Evolva’s contribution in the proposed merger, fairly reflects its market value.
Reinach, Switzerland, 20 October 2009. Arpida Ltd (SIX: ARPN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has reached a negative opinion on the market authorisation application (MAA) for intravenous iclaprim in complicated Skin and Soft Tissue Infections (cSSTI) in the European Union. Subsequently, Arpida decided to withdraw the MAA
Reinach/Allschwil, Switzerland, 10 September 2009. Arpida Ltd. (“Arpida”) and Evolva SA (“Evolva”), two Swiss biotech companies, today announced that they intend to merge the two companies subject to definitive agreement and shareholder approval. Arpida is listed on the Swiss stock exchange (SIX Swiss Exchange: ARPN) while Evolva is a privately-held company with headquarters near Basel and operations in Denmark, USA and India. The intended merger creates a company with promising growth prospects based on a pipeline of clearly differentiated drug candidates addressing major medical needs and a number of discovery partnerships generating significant revenues.
Reinach, Switzerland, 7 May 2009. The Annual General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors. A total of 90 shareholders were present at the meeting that took place in Reinach today. 4,629,711 shares were represented, or 21.9% of the total number of shares issued (21,094,104).
Reinach, Switzerland, 7 May 2009 – Arpida Ltd. (SIX: ARPN) will today discuss potential strategic scenarios with its shareholders during the Annual General Meeting (AGM) which starts at 10am CET in Reinach, Switzerland.
FDA requests an additional clinical study prior to approval
Arpida confirms progress of restructuring
Reinach, Switzerland, 19 January 2009 – Arpida Ltd. (SWX: ARPN) announces today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for intravenous iclaprim for the treatment of complicated skin and skin structure infections (cSSSI). The FDA indicated in its letter that they cannot approve the application for iclaprim in its current form and that additional clinical data are required to demonstrate efficacy in order to gain approval.
